In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The company’s shares closed yesterday at $201.68. Devarakonda ...

In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $202.46, changing hands for $203.87/share. When a stock reaches the target an ...

Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (XTRA:4AB) from Hold to Buy. As of October 21, 2024, the average one-year price target for AbbVie is 189 ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

Each month, we take a close look at an aspect of sector investing. This month, we are examining growth and valuation. Investors hunting for stocks that reasonably balance long-term growth ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 million upfront to form a new drug discovery pact with Gedeon Richter.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

After being rejected twice before, AbbVie’s latest Parkinson’s drug finally has been approved by the U.S. Food & Drug Administration. Findings from clinical studies of the drug, called Vyalev ...

For years, AbbVie's (ABBV) blockbuster rheumatoid-arthritis treatment, Humira, which launched in 2002, was the world's best-selling drug. Cigna said in August that it would remove Humira from some ...

AbbVie (NYSE:ABBV) will report third-quarter results next week and I expect to see a continuation of trends from the first half of the year with top and bottom-line beats and an improved full-year ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. With Humira revenue degrading, it would be wise to wait for evidence of a revenue replacement before ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...